This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Indigenous healthcare systems: different indigenous healthcare systems have different medication access. Pathways through tribal health systems differ from mainstream healthcare.
On post #28 — agreed on the reasoning, with one qualification.
United States: FDA licenses compounds. Prescribing and pharmacy practice are state-regulated. Compounds are prescription-only. Coverage is decided by individual plans, not nationally.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Telehealth prescribing: widespread in the US and varying in quality. Models without a clinician reviewing measurements and history are not recommended by this community.
Canada: Health Canada licenses compounds. Prescribing is provincial. Compounds are prescription-only. Coverage varies between public and private insurance.
This follows post #34 rather than contradicting it.
Provincial formularies in Canada are published and are the correct source for coverage information. Coverage for weight management is less common than for diabetes.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
On post #37 — agreed on the reasoning, with one qualification.
Telehealth prescribing: widespread in the US and varying in quality. Models without a clinician reviewing measurements and history are not recommended by this community.
post #41 answers the question as asked. The question underneath it is different.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Provincial formularies in Canada are published and are the correct source for coverage information. Coverage for weight management is less common than for diabetes.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
post #45 is right about the mechanism and I think understates the practical bit.
Prior authorisation, step therapy, and exclusion of weight-management indications from coverage are common access barriers. The denial letter tells you which barrier you are facing.
I read post #45 twice before replying, because I had assumed the opposite.
United States: FDA licenses compounds. Prescribing and pharmacy practice are state-regulated. Compounds are prescription-only. Coverage is decided by individual plans, not nationally.
Indigenous healthcare systems: different indigenous healthcare systems have different medication access. Pathways through tribal health systems differ from mainstream healthcare.
Private insurance gaps: some people have private insurance but medication is not covered. Manufacturer assistance programmes are the main resource for cost reduction.
Picking up post #48: that is the part I would want checked first.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Canadian access and provincial variation
Posting this under the heading it deserves: Canadian access and provincial variation Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category…
|
+74 | 80 | 7.7k | 18mo |
|
Revisiting: US compounding rules and how they changed
On the subject in the title: Revisiting: US compounding rules and how they changed Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category expires. As…
|
+5 | 9 | 26k | 23mo |
|
Second pass at: Coverage in the US: a map of the usual obstacles
On the subject in the title: Second pass at: Coverage in the US: a map of the usual obstacles Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
|
4 | 62k | 9mo | |
|
Coming back to: Telehealth prescribing models in the US
Posting this under the heading it deserves: Telehealth prescribing models in the US Everything below is what sits behind that. Documenting an access outcome, dated, because everything in this category…
|
+26 | 30 | 17k | 17h |
|
Canadian access and provincial variation — one year on
Canadian access and provincial variation — one year on Writing it up because I had to work it out twice and would rather nobody else did. Documenting an access outcome, dated, because everything in this…
|
+43 | 47 | 964 | 12mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
About the North America category
US and Canadian regulation, compounding, and coverage. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its author and a note. If the scope…
|
+3 | 7 | 43k | 9mo |
|
What changed in 2026, by region — does this still hold?
What changed in 2026, by region — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Documenting an access outcome, dated, because everything in…
|
+20 | 25 | 50k | 1d |
|
Coming back to: Official shortage notices and what they authorise
Official shortage notices and what they authorise Writing it up because I had to work it out twice and would rather nobody else did. A coverage question with the paperwork detail included, since that is what…
|
+85 | 92 | 5.5k | 11mo |
|
Coverage for the indication versus for the drug — a second dataset
On the subject in the title: Coverage for the indication versus for the drug — a second dataset Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is…
|
+46 | 50 | 41k | 16mo |
|
Second pass at: Coverage in the US: a map of the usual obstacles
On the subject in the title: Second pass at: Coverage in the US: a map of the usual obstacles Working notes rather than a conclusion. A coverage question with the paperwork detail included, since that is what…
|
4 | 62k | 9mo |